the Drug Information System of the Health Care Insurance Board
[Genees-en hulpmiddelen Informatie Project (GIP), College voor zorgverzekeringen (CVZ)]
The Netherlands

  • Objectives
  • Register: Input
  • Output from GIPdatabank
  • How it works
  • Drug monitoring and publications
  • More information, Inquiries?

    • Objectives


    The GIP is an information system of the Health Care Insurance Board, in use since 1988, containing information on expenditure on (extramural) drugs (= geneesmiddelen ) in the Netherlands and the degree to which they are used. The register includes prescription-related data on drugs that are:

  • prescribed by general practitioners and specialists;
  • and dispensed by pharmacists, dispensing general practitioners and other outlets;
  • as well as being reimbursed under the Health Care Insurance Act.

    • The information system also contains prescription-related data on medical aids under the Health Care Insurance Act (= hulpmiddelen):

  • prescribed by general practitioners and specialists;
  • dispensed by pharmacists, dispensing general practitioners and other outlets.
    •  


    Top
    Register: input

    The GIP databases contain data from a representative sample of more than 12 million people (3/4 of the Dutch population). The sample has been obtained from eighteen health insurance organisations and has been extrapolated to the size of the entire dutch population.
    For each prescription the following information is available:

  • patient-related: identification, gender, age and region;
  • drug-specific: name, dosage form, ATC-code, defined daily dose (DDD);
  • prescribers: general practitioners or type of specialists;
  • dispensers: pharmacists, dispensing general practitioners and other outlets;
  • prescription: date, dispensed amount and prescribed daily dose (PDD);
  • cost: pharmacy price, dispensing fee, VAT, reimbursement and personal contribution.

    • Top
    Output from GIPdatabank

    Output statistics are generated on all five ATC-levels. The following output statistics, which refer to the drug consumption of the total population, are provided by the GIPdatabank:
  • the total cost reimbursed;
  • the number of patients receiving at least one prescription;
  • the number of DDD's;
  • the number of prescriptions;


    • as well as computed statistics such as:
  • total costs per patient receiving at least one prescription;
  • number of DDD's per patient;
  • total cost per DDD;
  • number of prescriptions per patient;
  • total costs per prescription;
  • number of DDD's per prescription.

    Top
    How it works

    Since April 2005, consumer data at all ATC-levels have been publicly available on this website. Making a choice from “Geneesmiddelen” (drugs) takes you to consumer data with the ATC-classificy (2004) from the World Health Organization (WHO). If you know the ATC-code of the drug you are looking for, you can find it with ‘zoeken’.
    Making a choice from ‘Hulpmiddelen’ (medical technical aids for persons with disabilitites) takes you to consumer data with the classificy of Iso 9999 (2002).
    Afterwards you can chooce between different reports.

    If you want to see other key data, choose this in the last menu at the top.

    Geneesmiddelen
    Totale Kosten=Total Cost excluding co-payment
    gebruikers=Users
    DDD=DDD
    Voorschriften=Presciption
    tk/gebr=Total cost per User
    ddd/gebr=DDD per User
    tk/ddd=Total cost per DDD
    vs/gebr=Presciptions per user
    TK/VS=total cost per prescription
    DDD/VS=DDD per prescription

    Hulpmiddelen
    Totale Kosten=Total Cost excluding co-payment
    gebruikers=Users
    Declaraties=Presciption
    tk/gebr=Total cost per User
    decl/gebr=Presciptions per user
    TK/del=total cost per prescription
    Top
    Drug monitoring and publications

    The GIP information system is a powerful monitoring instrument for preparing and evaluating policy measures and forecasting costs and developments in consumption in the near future. It also can be used to estimate the extra costs of introducing new drugs into the reimbursement scheme, and to provide insurance organisations with detailed information about developments in the drug usage of their insured population in comparison with other organisations.

    List of relevant publications:

    • GIPeilingen, key statistics on drug consumption in the Netherlands;
    • GIPsignalen, special reports about the use of a specific group of pharmaceuticals;


    • benzodiazepines (2001);
    • peptic ulcer drugs (2002);
    • lipid-reducing drugs (2002);
    • antidepressants (2003);
    • diabetics (2005).
    Top
    More information, Inquiries?

    Health Care Insurance Board
    GIP / Afdeling Verantwoording en Signalering
    P.O. Box  320
    1110 AH  Diemen
    The Netherlands
    J.F. Piepenbrink MSc, advisor
    Telephone: +31 20 797.86.86
    E-mail: infogip@cvz.nl
    corporate site of cvz
    Top

    (*) The Health Care Insurance Board (CVZ)

     

    The Health Care Insurance Board (CVZ) co-ordinates the implementation and funding of the Health Insurance Act and the AWBZ (Exceptional Medical Expenses Act). The CVZ takes up an independent position: in between policy and practice; in between central government on the one hand and the health insurers, care-providers and citizens on the other. 
    The tasks of the CVZ are laid down in statutes. The most well-known of these are:

    • Providing advice on the sum for contributions and the budgets for health insurers;
    • Managing contribution funds and distributing them over the health insurers;
    • Providing guidelines for carrying out new and existing legislation;
    • Monitoring adherence to the regulations of international conventions;
    • Informing health insurers, care-providers and citizens;
    • Monitoring the feasibility and efficiency of government plans;
    • Detecting and reporting bottlenecks in the practice of implementation. 

    The CVZ comprises an executive board appointed by the Minister of Health, Welfare and Sport and a supportive organisation under the guidance of a management board. The executive board comprises seven independent executives.

     

     

    		•
    Beschrijving van het Genees- en hulpmiddelen Informatie Project
    Over het GIP
     
    Veelgestelde vragen
     
    Toelichting GIP-databank
     
    Links
     
    Actueel
     
    GIP-publicaties
     
    Beleidsmaat-regelen
     
    Nieuwsbrief
     
    Reageer
     
    English General information